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ABSTRACT: Cyclic tetrapeptide and depsipeptide natural
products have proven useful as biological probes and drug
candidates due to their potent activities as histone deacetylase
(HDAC) inhibitors. Here, we present the syntheses of a class
of cyclic tetrapeptide HDAC inhibitors, the azumamides, by a
concise route in which the key step in preparation of the
noncanonical disubstituted β-amino acid building block was an
Ellman-type Mannich reaction. By tweaking the reaction
conditions during this transformation, we gained access to the
natural products as well as two epimeric homologues. Thus,
the ﬁrst total syntheses of azumamides B−D corroborated the
originally assigned structures, and the synthetic eﬀorts enabled the ﬁrst full proﬁling of HDAC inhibitory properties of the entire
selection of azumamides A−E. This revealed unexpected diﬀerences in the relative potencies within the class and showed that
azumamides C and E are both potent inhibitors of HDAC10 and HDAC11.
■ INTRODUCTION
Macrocyclic peptides have played important roles in the ﬁeld of
epigenetics due to their potent activities as inhibitors of histone
deacetylase (HDAC) enzymes. One of the two HDAC target-
ing drugs (11 and 3) that are approved by the U.S. Food and
Drug Administration (FDA) for clinical treatment of cutaneous
T-cell lymphoma is the macrocyclic natural product romidepsin
(3).2 Furthermore, a cyclic tetrapeptide, trapoxin,3 played an
instrumental role in the ﬁrst isolation of a mammalian HDAC
enzyme.4,5 Thus, this class of inhibitors holds promise as tool
compounds as well as potential drug candidates targeting
HDACs.6−9
Though clearly bearing an overall resemblence to the classical
cyclic tetrapeptide HDAC inhibitors [including, for example,
apicidin (4)],10 the azumamides (5−9) are structurally unique
in that their extended Zn2+-coordinating amino acid (shown in
yellow in Figure 1) is a disubstituted β-amino acid.11 Further-
more, we found the azumamides interesting due to the relatively
strong potencies reported for azumamide E against class I
HDACs12 in spite of its weak Zn2+-coordinating carboxylic acid
functionality.13 Previously, azumamide A14,15 and azumamide
E12,14−16 have been prepared by multistep chemical syntheses,
but only azumamide E was tested against recombinant HDAC
isoforms 1−9.12 Furthermore, in vitro proﬁling with recombi-
nant HDACs has witnessed important new developments since
the publication of those results.17,18 We therefore found it
relevant to explore the properties of these macrocycles in more
detail by preparing the complete selection of natural products
(5−9), and proﬁling their activities against the full panel of
recombinant human Zn2+-dependent HDAC enzymes, HDAC1−11.
As total syntheses of azumamides B−D had not been reported
previously, this work would also allow unequivocal validation of
the proposed structures.11
For syntheses of the azumamides, we envisaged two
signiﬁcant challenges: ﬁrst, eﬃcient stereoselective synthesis
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Figure 1. Structures of archetypical HDAC inhibitors (1−4) and
target azumamides 5−9.
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of the disubstituted β-amino acid, and second, the macro-
cyclization step, which is known to be diﬃcult for small cyclic
peptides in general19 and furthermore proved challenging in
previously reported syntheses of azumamide analogues.12
■ RESULTS AND DISCUSSION
Building Block Synthesis. For our synthesis of the β-amino
acid building block, we chose a diastereoselective Ellman-type
Mannich reaction to set the stereochemistry, as also previously
reported by Ganesan and co-workers.15 However, to avoid having
this important transformation at a late stage in our synthetic route,
we decided to optimize this reaction between a propionate ester
and a simple imine as shown in eq 1.
This should give an intermediate with the correct stereo-
chemistry (2S,3R), which could be readily elaborated to give
the desired β-amino acid by robust organic synthetic trans-
formations (vide infra). Mannich reactions between ester
enolates and chiral sulﬁnylimines have been studied exten-
sively,20,21 and using previously reported conditions as our
starting point we conducted an optimization study as outlined
in Table 1. The tert-butyl ester showed superior selectivity
(entry 5) compared to the less bulky methyl, ethyl, allyl, and
PMB esters (entries 1−4), and furthermore, the methyl ester
did not proceed to completion in our hands. Somewhat
surprisingly, however, the major diastereoisomer in entry 5
proved to have (2S,3S) conﬁguration as determined by X-ray
crystallography upon desilylation (Figure 2).
This indicates that the pathway leading to our major isomer
did not proceed through the six-membered Zimmerman−
Traxler-type transition state,22 which has been proposed to be
responsible for the diastereoselectivity with similar sub-
strates.20,23 By using HMPA as an additive instead of a Lewis
acid, this reaction has previously been shown to proceed
through a diﬀerent transition state,20 and indeed we saw the
same product distribution when using HMPA and TiCl(OiPr)3
as additives with our substrates (entries 5 and 6). This indicates
that the six-membered transition state, where coordination of
titanium is crucial, is highly unlikely to play a signiﬁcant role in
the formation of our major isomer. This is not in agreement
with the diastereoselectivities observed with the substrates reported
by Ganesan and co-workers.15 Thus, to address whether the steric
bulk of the triisopropylsilyl ether was responsible for interrupting
the six-membered transition state, we performed the reaction with
diﬀerent means of protecting the alcohol (entries 7−9). No
signiﬁcant eﬀect was observed, however, indicating instead that the
steric bulk of the tert-butyl ester caused the predominance of a
diﬀerent transition state when using our substrates. This is also in
agreement with the original study by Tang and Ellman20 where the
level of selectivity decreased for 2,3-disubstituted β-amino acids
when the bulk of the ester increased from methyl to tert-butyl.
Because we were interested in taking advantage of solid-
phase synthesis methods to prepare the linear tetrapeptide
azumamide precursors with a minimum of chromatographic
puriﬁcation steps, we were keen on keeping the acid-labile tert-
butyl ester protecting group, which would allow easy protecting
group manipulation to give an Fmoc-protected β-amino acid
building block. Hence, instead of substituting this protecting
group, we decided to optimize the Mannich reaction conditions
to deliver the desired stereochemistry. First, we changed the
stereochemistry of the sulﬁnylimine to the R-enantiomer, which
expectedly furnished the enantiomer of entries 5−9 (2R,3R) as
the major isomer (entry 10). We then hypothesized that the
conﬁguration of the 2-position would be sensitive to the E/Z
conﬁguration of the enolate. Using Ireland’s conditions for
forming the enolate in the presence of HMPA,24,25 we achieved
>80% Z-isomer, which gratifyingly aﬀorded the (2S,3R)
product as major isomer (entry 11). Under the developed
conditions, we prepared compound 12, which was further
elaborated to give Fmoc-protected β-amino acid 16 in 15%
overall yield with just four column chromatographic puriﬁcation
steps from compound 10 (Scheme 1).
Table 1. Optimization of Stereochemical Outcome of the Mannich Reaction Shown in Equation 1
entry auxiliary* R1 R2 additive enolatea drb major isomer
1 R Me OSi(iPr)3 TiCl(O
iPr)3 E 47:39:10:4 ND
c
2 R Et OSi(iPr)3 TiCl(O
iPr)3 E 49:29:11:11 ND
3 R allyl OSi(iPr)3 TiCl(O
iPr)3 E 46:34:10:10 ND
4 R PMB OSi(iPr)3 TiCl(O
iPr)3 E 46:33:11:10 ND
5 R tBu OSi(iPr)3 TiCl(O
iPr)3 E 60:26:8:6 (2S,3S)
d
6 R tBu OSi(iPr)3 HMPA E 71:15:14:0 (2S,3S)
7 R tBu OBn TiCl(OiPr)3 E 70:18:12:0 ND
8 R tBu OPMB TiCl(OiPr)3 E 77:13:10:0 (2S,3S)
9 R tBu OSi(Et)3 TiCl(O
iPr)3 E 75:21:4:0 (2S,3S)
d
10 S tBu OSi(iPr)3 HMPA E 77:18:5:0 (2R,3R)
e
11 S tBu OSi(iPr)3 HMPA
f Z 64:25:8:2 (2S,3R)g
aMajor conﬁguration of the enolate as determined by NMR and by trapping with tBuMe2SiCl.
bDiastereomeric ratio determined by 1H NMR.
cND = not determined. dDetermined by X-ray crystallography on its desilylated homologue. eDetermined spectroscopically by comparison with its
enantiomer from entries 5 and 9. fHMPA (5.4 equiv) was added prior to the substrate to obtain the (Z)-enolate (>80%). gDetermined by
comparison of spectroscopic data of the fully elaborated Boc-protected β-amino acid with previously reported data.12
Figure 2. X-ray crystal structure of the (2S,3S) precursor obtained by
desilylation of the major product in entry 5 of Table 1.
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The Boc-protected homologue of 16 was also prepared to
conﬁrm the (2S,3R) stereochemistry by comparison of
spectroscopic data (optical rotation and NMR) with those
previously reported (Figure S1 in Supporting Information).12
Furthermore, the β2- and β3-epimeric building blocks were
prepared by elaboration of the major isomers from entries 10
and 5, respectively (see Supporting Information for details).
Although the achieved diastereomeric ratios were not par-
ticularly impressive, this strategy very nicely provided the
correct stereochemistry along with two novel β-amino acids,
enabling investigation of the biochemical eﬀect of stereo-
chemical conﬁguration at these two chiral centers.
Cyclic Peptide Synthesis. Because three diﬀerent points of
cyclization had been reported for azumamide E and since these
were all performed with diﬀerent coupling reagents,12,14,15 we
performed cyclization experiments using a simpliﬁed model
peptide to address the issue. Not too surprisingly, this showed
that macrolactamizations with the most sterically hindered
amino acids at the C-terminal were particularly poor, resulting
in signiﬁcant amounts of N-terminal guanidinylation, incom-
plete cyclization, epimerization, and/or dimerization (Table S1
in Supporting Information). Thus, we prepared the linear
tetrapeptides 17, 19, and 21 on solid support by standard Fmoc
solid-phase synthesis using β-amino acid 16 and commercially
available Fmoc-D-amino acids.
In Scheme 2A, the cyclization was then performed at the
β-amino acid position and in Scheme 2B at the alanine residue,
whereas the preparation of azumamide D (8) was achieved by
cyclization between the two least sterically challenging alanine
residues (Scheme 2C). After cleavage from the 2-chlorotrityl
polystyrene resin with dilute TFA, the linear tetramers were
ring-closed by use of HATU under dilute conditions (0.4−
0.5 mM),26−29 and furthermore slow addition of the linear
peptide by syringe pump to a solution of Hünig’s base and
HATU, as described by Ganesan and co-workers,15 was tested.
Judging from LC−MS analyses of the reaction mixtures, we
could not observe any signiﬁcant diﬀerences between the cycliza-
tion yields obtained with the diﬀerent methods. Although all
the couplings proceeded satisfactorily, with full conversion of
linear peptides and minor amounts of the corresponding dimers
as the only observed byproducts, the resulting overall isolated
yields were relatively low (∼10%). We ascribe this to diﬃculties
during puriﬁcation of the macrocyclic products by preparative
reversed-phase HPLC caused by poor water solubility, as we
were able to recover more material by purifying the macrocycles
by column chromatography. Unfortunately, however, this did
not provide the ﬁnal compounds in satisfyingly high purity for
the bioassays, and thus the ﬁnal compounds were all subjected
to preparative reversed-phase HPLC puriﬁcation although this
resulted in a loss of material. Carbodiimide-mediated amidation
of the side chain was attempted for conversion of 7 to 6 and 23
to 8, but the reaction was slow and gave varying yields (6 vs 8,
Scheme 2). Instead, HATU-mediated coupling was attempted
for conversion of 9 to 5, and this proved faster and gave an
acceptable yield (5). Spectral data of all the natural products
5−9 were in excellent agreement with those originally reported
for the azumamides isolated from natural sources,5 thus
corroborating the original structural assignment (Figures S2−S6
in Supporting Information). Finally, the two epimeric β-amino
acid building blocks were applied in analogous syntheses of
β3-epi-azumamide E (26) and β2-epi-azumamide E (29) as
shown in Scheme 3.
HDAC Screening. As an initial test of the HDAC inhibitory
potency of all seven compounds, we ﬁrst screened against the
full panel of recombinant human HDACs at two compound
concentrations (50 μM and 5 μM). Protocols for HDAC1−9
were adapted from Bradner et al.,18 using the ﬂuorogenic
Ac-LeuGlyLys(Ac)-AMC substrate for HDAC1−3 and 6 while
using the Ac-LeuGlyLys(tfa)-AMC substrate for HDAC4, 5,
and 7−9. For HDAC10 we used the tetrapeptide Ac-ArgThr-
Lys(Ac)Lys(Ac)-AMC,30 which was recently reported to
perform well with this enzyme.31 Finally, for HDAC11, we
also used Ac-LeuGlyLys(Ac)-AMC as substrate.32
The site-speciﬁcally epimerized compounds exhibited no
activity as previously reported for an analogue having both
stereocenters inverted.7 It was not surprising that 26 was
inactive, but it is noteworthy that the subtle change of inverting
the stereochemistry of a single methyl group in 29 had such a
detrimental eﬀect across the entire selection of enzymes
(Figure 3). Furthermore, none of the compounds 5−9 were
able to inhibit class IIa HDAC activity against a triﬂuoroacety-
lated substrate (Figure 3).
Inhibitor Ki Values. Next, we performed dose−response
experiments for all compound−HDAC combinations that gave
above 50% inhibition in the initial assay (Figure S7 and Table
S2 in Supporting Information). The obtained IC50 values were
converted to Ki values by use of the Cheng−Prusoﬀ equation
[Ki = IC50/(1 + [S]/Km)] with the assumption of a standard
fast-on−fast-oﬀ mechanism of inhibition. Reported Km values
were applied for the calculations except HDAC10, where we
determined the Km for the used substrate to be 1.5 ± 0.2 μM
(Figure 4).
Low potencies were recorded against HDACs 6 and 8, which
is in accordance with previous data for azumamide E (Table 2);6
however, compounds 7 and 9 were both potent inhibitors
of HDACs 10 and 11. Although they are classiﬁed together
Scheme 1. Synthesis of β-Amino Acid Building Block 16.a
aReagents and conditions: (a) HMPA (6.4 equiv), LDA (2.6 equiv),
11 (2.5 equiv), THF, −78 °C, 30 min; then 10, −78 °C, 30 min. (b)
AcOH (1.0 equiv), Bu4NF (2.0 equiv), THF, 0 °C → rt, 1.5 h. (c)
NaHCO3 (1.5 equiv), Dess−Martin periodinane (1.4 equiv), dry
CH2Cl2, 0 °C → rt, 1.5 h. (d) KHMDS (1.9 equiv), Ph3PBr-
(CH2)3COOEt (2.0 equiv), THF, −78 °C → rt, 18 h. (e) TFA−
CH2Cl2 (1:1, 10 mL, 80 equiv), 0 °C → rt, 3 h. (f) HCl (4.0 M in
dioxane, 3.0 equiv), dioxane, 3 h. (g) Na2CO3 (4.0 equiv), Fmoc-OSuc
(1.2 equiv), dioxane−H2O, 0 °C → rt, 2 h.
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(class IIb), HDACs 6 and 10 clearly interact very diﬀerently
with these inhibitors.
Generally, we found the compounds with a carboxylic acid
Zn2+-binding group (7 and 9) to be more potent than the
Scheme 3. Synthesis of the Two Epimers 26 and 29 of Azumamide E by Solid-Phase Synthesis Followed by Head-to-Tail
Macrolactamization in Solutiona
aReagents and conditions: (a) TFA−CH2Cl2 (1:1), 2 × 30 min. (b) HATU, iPr2NEt (8.0 equiv), DMF (0.3−0.7 mM peptide concn), 17−21 h. (c)
LiOH, THF−H2O (1:1).
Scheme 2. Synthesis of Azumamides A−E by Solid-Phase Synthesis Followed by Head-to-Tail Macrolactamization in Solutiona
aReagents and conditions: (a) TFA−CH2Cl2 (1:1), 2 × 30 min. (b) HATU, iPr2NEt (8.0 equiv), DMF (0.4−0.5 mM peptide concn), 17−21 h;
then HATU (0.5 equiv), 1−3 h [A, 11% 18 after preparative HPLC; B, 25% 20 after column chromatography; C, 19% 22 after column
chromatography]. (c) LiOH, THF−H2O (1:1). (d) DIC (11 equiv), HOBt (3.0 equiv), iPr2NEt (4.0 equiv), NH3−dioxane (25 equiv), DMF−
CH2Cl2 (2:1), 5 days, 67%. (e) HATU (2.0 equiv),
iPr2NEt (5.5 equiv), NH3−dioxane (25 equiv), DMF, 5.5 h, 40% (for steps c and e). (f) DIC
(6.0 equiv), HOBt (3.0 equiv), iPr2NEt (4.0 equiv), NH3−dioxane and NH3−MeOH (30 equiv), CH2Cl2−DMF (2:1), 13 days, 11% (for steps c and f).
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carboxamides (5, 6, and 8), which is in contrast to the originally
reported HDAC inhibition data obtained for the natural
products against an HDAC-containing cell extract.5 However,
the data presented herein agree with subsequent work from
Ganesan and co-workers15 on azumamide A (5) and azumamide
E (9). We thus show that this applies to all the azumamides,
which also conﬁrms that a carboxylate Zn2+-binding group
renders HDAC inhibitors signiﬁcantly more potent than a
corresponding carboxamide, as would be expected from
literature precendents.19,26,27 Furthermore, compound 7 was
more potent than 9 against HDACs 1−3, 6, 10, and 11, which
is also in contrast to the original evaluation that found azuE (9)
more potent than azuC (7) against crude enzymes from K562
cell extract.5 The tyrosine-containing compound (7) exhibited
∼2-fold higher potency against HDACs 1, 3, 6, 10, and 11,
whereas the phenylalanine-containing azumamide E (9) was only
more potent against HDAC8, albeit at micromolar Ki values.
Finally, the inhibition of HDAC11 by azumamides C (7) and
E (9) is, to the best of our knowledge, the ﬁrst demonstration
of potent cyclic peptide inhibitors of this isozyme.33 Notably,
these binding aﬃnities were achieved without the presence of a
strong Zn2+ chelator, such as hydroxamic acid.
■ CONCLUSIONS
In summary, we report total syntheses of all ﬁve azumamides,
including for the ﬁrst time azumamides B−D, which corro-
borate the originally proposed structures. Our synthetic route
furthermore enabled preparation of site-speciﬁcally edited
analogues for exploration of structure−activity relationships
(SAR).34−36 The HDAC proﬁling results show that the β-amino
acid residue, present in all the azumamides, is sensitive to even
slight modiﬁcations. In addition, the original HDAC testing
using cell extract indicated that azumamide E was the most
Figure 3. Single-dose HDAC inhibitory screening. Assays were per-
formed at 50 μM (shown) and 5 μM (not shown) peptide
concentrations. We chose <50% inhibition at 50 μM as our cutoﬀ to
sort away inactive compounds before performing full dose−response
experiments. All compound−enzyme combinations that were
discarded at this stage were tested in at least two individual assays
performed in duplicate. Error bars represent the standard deviation.
(*) Fusion protein of GST-tagged HDAC3 with the deacetylase
activation domain (DAD) of nuclear receptor corepressor (NCoR1).
Figure 4. Michaelis−Menten plot for HDAC10.
Table 2. Potencies of Azumamides against Zn2+-Dependent Histone Deacetylasesa
Ki values (nM)
class I class IIa class IIb class IV
compd HDAC1 HDAC2 HDAC3b HDAC8 HDAC4 HDAC5 HDAC7 HDAC9 HDAC6 HDAC10 HDAC11
5 (azuA) >5000 >5000 3200 >5000 52%c IAd IA IA IA IA >5000
6 (azuB) 5000 3000 3000 IA IA IA IA IA IA IA >5000
7 (azuC) 32 ± 1 40 ± 20 14 ± 1 >5000 IA IA IA IA 2000 10 ± 4 35 ± 3
8 (azuD) >5000 >5000 3700 IA IA IA IA IA IA IA >5000
9 (azuE) 67 ± 7 50 ± 30 25 ± 5 4400 IA IA IA IA >5000 20 ± 12 60 ± 16
26 (β3-epi-azuE) IA IA IA IA IA IA IA IA IA IA IA
29 (β2-epi-azuE) IA IA IA IA IA IA IA IA IA IA IA
1 (SAHA) 8 ± 1.5 7 ± 1.5 12 ± 4 700 ± 20 IA IA IA IA 22 ± 9 NTe 13 ± 2
3 (FK-228)f 0.002 0.038 0.15 0.15 20.5 550 1250 1100 10 NT NT
aIC50 values were determined from at least two individual dose−response experiments performed in duplicate (Figure S7 in Supporting
Information), and Ki values were calculated from the Cheng−Prusoﬀ equation.
bFusion protein of GST-tagged HDAC3 with deacetylase activation
domain NCoR1. cPercent inhibition at 50 μM inhibitor concentration. dIA = inactive (<50% inhibition at 50 μM [inhibitor], Figure 3). eNT = not
tested. fData from Bradner et al.18
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potent of the series, but the comprehensive proﬁling presented
herein shows that azumamide C is in fact ∼2-fold more potent
than azumamide E against the majority of the isozymes.
By taking advantage of the modular methodologies described
in this article and building on the gained SAR information, we
are currently investigating collections of azumamide analogues
in search of more potent and selective ligands based on this
promising scaﬀold.
■ EXPERIMENTAL SECTION
General. All chemicals and solvents were analytical-grade and were
used without further puriﬁcation. Vacuum liquid chromatography
(VLC) was performed on silica gel 60 (particle size 0.015−0.040 μm).
UPLC−MS analyses were performed on a Phenomenex Kinetex
column (1.7 μm, 50 × 2.10 mm) by use of a Waters Acquity ultra-
high-performance liquid chromatography system. A gradient with
eluent I (0.1% HCOOH in water) and eluent II (0.1% HCOOH in
acetonitrile) rising linearly from 0% to 95% II during t = 0.00−2.50
min was applied at a ﬂow rate of 1 mL/min (gradient A) or during
t = 0.00−5.20 min (gradient B). Analytical HPLC was performed on a
Phenomenex Luna column [150 mm × 4.6 mm, C18 (3 μm)] by use of
an Agilent 1100 LC system equipped with a UV detector. Gradient C,
with eluent III (0.1% TFA in water) and eluent IV (0.1% TFA in
acetonitrile) rising linearly from 0% to 95% IV during t = 2−20 min,
was applied at a ﬂow rate of 1 mL/min. Preparative reversed-phase
HPLC was performed on a Phenomenex Luna column [250 mm ×
20 mm, C18 (5 μm, 100 Å)] by use of an Agilent 1260 LC system
equipped with a diode-array UV detector and an evaporative light
scattering detector (ELSD). A gradient, with eluent V (95:5:0.1, water−
MeCN−TFA) and eluent VI (0.1% TFA in acetonitrile) rising linearly
from 0% to 95% IV during t = 5−45 min, was applied at a ﬂow rate of
20 mL/min. All tested compounds were puriﬁed to homogeneity and
shown by both analytical HPLC (gradient C) and LC−MS (gradient A)
to be of more than 95% purity. One- and two-dimensional NMR spectra
were recorded on a Varian Mercury 300 instrument or a Varian INOVA
500 MHz instrument. All spectra were recorded at 298 K. Correlation
spectroscopy (COSY) spectra were recorded with a relaxation delay of
1.5 s before each scan, a spectral width of 6k × 6k, and eight FIDs and
1k × 512 data points collected. Heteronuclear single quantum coherence
(HSQC) spectra were recorded with a relaxation delay of 1.5 s before
each scan, a spectral width of 6k × 25k, and 16 FIDs and 1k × 128 data
points collected. Heteronuclear two-bond correlation (H2BC) spectra
were recorded with a relaxation delay of 1.5 s before each scan, a spectral
width of 4k × 35k, and 16 FIDs at 295 K and 1k × 256 data points
collected. Heteronuclear multiple-bond correlation (HMBC) spectra
were recorded with a relaxation delay of 1.5 s before each scan, a spectral
width of 6k × 35k, and 32 FIDs and 1k × 256 data points collected.
Chemical shifts are reported in parts per million (ppm) relative to
deuterated solvent peaks as internal standards (δH, DMSO-d6 2.50 ppm;
δC, DMSO-d6 39.52 ppm, δH, CD3OH 3.30 ppm; δH, CDCl3 7.26 ppm;
δC, CDCl3 77.16 ppm). Coupling constants (J) are given in hertz (Hz).
Multiplicities of 1H NMR signals are reported as follows: s, singlet; d,
doublet; t, triplet; q, quartet; m, multiplet.
General Procedure for Mannich Reactions. A solution of LDA
(2.1 equiv) was added dropwise to a solution of the ester (2.0 equiv)
in dry THF at −78 °C. After the mixture was stirred for 30 min,
Ti(O-iPr)3Cl (4.2 equiv) in dry THF was added dropwise. The orange
solution was stirred for 30 min and the imine (1.0 equiv) in dry THF
was added dropwise. The mixture was stirred for 3 h or until thin-layer
chromatography (TLC) showed full conversion of the imine. The
mixture was quenched with saturated aqueous NH4Cl and allowed to
reach room temperature. Water was added and the mixture was
decanted into a separatory funnel. EtOAc−water (1:1) was added to
the remaining Ti precipitate, and the mixture was stirred vigorously for
5 min before being added to the separatory funnel. The aqueous phase
was extracted with EtOAc and the combined organic phases were
washed again with water, dried (MgSO4), ﬁltered, and concentrated in
vacuo.
Azumamide A, (Z)-6-[(2R,5R,8R,11R,12S)-8-Benzyl-2-iso-
propyl-5,12-dimethyl-3,6,9,13-tetraoxo-1,4,7,10-tetraazacy-
clotridecan-11-yl]hex-4-enamide (5). LiOH (89 mg, 3.72 mmol,
85 equiv) in water (4.0 mL) was added to a stirred solution of the
impure cyclic peptide 20 (24.2 mg, approximately 0.045 mmol) in
THF (4 mL). After 2.5 h of stirring, the organic solvent was removed
in vacuo. The aqueous phase was acidiﬁed with 1 M HCl to pH 2 and
extracted with EtOAc (4 × 30 mL) and CH2Cl2 (40 mL). The organic
phases were dried (Na2SO4), ﬁltered, and concentrated to aﬀord crude
azumamide E, which was used without further puriﬁcation. Analytical
UPLC−MS gradient A, tR = 1.47 min. To a solution of the above
crude azumamide E (≈0.045 mmol) in DMF (3.0 mL) were added
HATU (34 mg, 0.09 mmol, 2 equiv), iPr2NEt (43 μL, 0.25 mmol,
5.5 equiv), and, after 5 min, NH3−dioxane (0.9 mL, 0.45 mmol,
10 equiv). After 1 h, NH3−dioxane (0.45 mL, 0.23 mmol, 5 equiv)
was added. UPLC−MS analysis showed 50% conversion after 3 h, and
HATU (34 mg, 0.09 mmol, 2 equiv) and NH3−dioxane (0.45 mL,
0.23 mmol, 5 equiv) were added. After an additional 1 h, DMF
(1.0 mL) followed by HATU (17 mg, 0.045 mmol, 1 equiv) and
NH3−dioxane (0.45 mL, 0.23 mmol, 5 equiv) were added, and stirring
was continued for 1 h before concentration in vacuo. The residue was
dissolved in MeCN−H2O and puriﬁed by preperative HPLC to give
azumamide A (5) (4.8 mg, 12% overall). [α]D +56° (c = 0.2, MeOH);
previously reported11 [α]D +33° (c = 0.1, MeOH).
1H NMR (500 MHz,
CD3OH) δ 8.18 (d, J = 8.6 Hz, 1H), 8.16 (d, J = 9.0 Hz, 1H), 7.72
(d, J = 8.2 Hz, 1H), 7.59 (m, 2H), 7.20 (m, 5H), 6.74 (br s, 1H), 5.48
(m, 1H), 5.37 (m, 1H), 4.33 (dt, J = 9.0, 7.0 Hz, 1H), 4.24 (m, 2H),
3.81 (dd, J = 10.4 Hz and 8.4 Hz, 1H), 3.10 (m, 2H), 2.72 (m, 1H),
2.57 (dt, J = 14.1, 6.9 Hz, 1H), 2.41 (m, 2H), 2.27 (m, 4H), 1.30 (d,
J = 7.5 Hz, 3H), 1.23 (d, J = 7.3 Hz, 3H), 0.96 (d, J = 6.5 Hz, 3H), 0.94
(d, J = 6.7 Hz, 3H). HRMS (ESI-TOF) m/z calcd for C27H38N4O7H
+
514.3029; found 514.3032 [M + H]+. HPLC gradient C, tR = 11.62
min (>95%).
Azumamide B, (Z)-6-[(2R,5R,8R,11R,12S)-8-(4-Hydroxyben-
zyl)-2-isopropyl-5,12-dimethyl-3,6,9,13-tetraoxo-1,4,7,10-tet-
raazacyclotridecan-11-yl]hex-4-enamide (6). An aqueous sol-
ution of LiOH (0.5 M, 55 μL, 2.0 mmol, 2.5 equiv) was added to the
cyclic peptide 18 (6.1 mg) in THF−H2O (1:1, 2 mL) at 0 °C. After
30 min the ice bath was removed. Additional portions of LiOH
solution (55 μL, 2.0 mmol, 2.5 equiv) were added after 2, 4, and 6 h,
and stirring was continued for an additional 19 h to ensure full
conversion. Then water (0.5 mL) was added and the organic solvent
was removed in vacuo. The aqueous phase was acidiﬁed with 1 M HCl
and extracted with EtOAc (5 × 20 mL). The organic phase was
dried (Na2SO4), ﬁltered, and concentrated in vacuo to aﬀord the
crude azumamide C, which was used without further puriﬁcation.
To a solution of crude azumamide C (5.8 mg, 10.9 μmol) in DMF
(2 mL) were added HOBt (4.4 mg, 33 μmol, 3 equiv), DIC
(5.1 μL, 34 μmol, 3 equiv), and iPr2NEt (7.6 μL, 44 μmol, 4 equiv).
After 10 min, NH3−dioxane (0.5 M, 0.11 mL, 55 μmol, 5 equiv) was
added. After 1.5 h, DIC (5 μL, 34 μmol, 3 equiv) was added, followed
by NH3−dioxane (0.5 M, 0.11 mL, 55 μmol, 5 equiv). After the
mixture was stirred for 16 h, additional DIC (2 equiv) and NH3−
dioxane (5 equiv) were added, and this procedure was repeated once
more after 18 h. Finally, CH2Cl2 (1 mL) was added, followed by DIC
(3 equiv) and NH3−dioxane (10 equiv), and after 2 days of stirring at
room temperature, the reaction mixture was concentrated, dissolved
in MeCN−H2O (2:1), and puriﬁed by preparative HPLC to give
azumamide B (6) (3.6 mg, 62%, two steps) as a white solid. [α]D +65°
(c = 0.15, MeOH); previously reported11 [α]D +45° (c = 0.1, MeOH).
1H NMR (500 MHz, CD3OH) δ 8.13 (d, J = 7.9 Hz, 1H), 8.00 (d, J =
8.9 Hz, 1H), 7.85 (d, J = 7.2 Hz, 1H), 7.61 (d, J = 8.2 Hz, 1H), 7.01
(d, J = 8.4 Hz, 3H), 6.67 (d, J = 8.4 Hz, 3H), 5.49 (m, 1H), 5.37 (dd,
J = 18.0 and 7.3 Hz, 2H), 4.29 (pentet, J = 7.2 Hz, 1H), 4.15 (m, 1H),
4.05 (m, 1H), 3.60 (m, 1H), 3.13 (dd, J = 13.7, 10.1 Hz, 1H), 3.00
(dd, J = 13.8, 6.3 Hz, 1H), 2.70 (m, 2H), 2.36 (ddd, J = 22.3, 21.5, 7.1
Hz, 11H), 1.29 (d, J = 7.2 Hz, 3H), 1.27 (d, J = 7.4 Hz, 3H), 0.95 (d,
J = 5.7 Hz, 3H), 0.93 (d, J = 6.0 Hz, 3H). HRMS (ESI-TOF) m/z
calcd for C27H39N5O6H
+ 530.2978; found 530.2973 [M + H]+. HPLC
gradient C, tR = 10.31 min (>95%).
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Azumamide C, (Z)-6-[(2R,5R,8R,11R,12S)-8-(4-Hydroxyben-
zyl)-2-isopropyl-5,12-dimethyl-3,6,9,13-tetraoxo-1,4,7,10-tet-
raazacyclotridecan-11-yl]hex-4-enoic Acid (7). LiOH (49 mg,
2.0 mmol, 35 equiv) in water (5.0 mL) was added to the crude cyclic
peptide 18 (61 mg) in THF (5.0 mL). The solution was stirred for
16 h and concentrated in vacuo. The resulting residue was dissolved in
THF−H2O (1:1, 10 mL) by adding a few drops of TFA, and then
puriﬁcation by preparative HPLC aﬀorded azumamide C (7) (2.2 mg,
9% overall) as a white solid. [α]D +49° (c = 0.14, MeOH); previously
reported11 [α]D +21° (c = 0.1, MeOH).
1H NMR (500 MHz,
CD3OH) δ 8.08 (d, J = 7.7 Hz, 1H), 7.99 (d, J = 8.4 Hz, 1H), 7.84
(s, 1H), 7.62 (d, J = 8.1 Hz, 1H), 7.01 (d, J = 8.4 Hz, 2H), 6.67 (d,
J = 8.4 Hz, 2H), 5.48 (t, J = 8.8 Hz, 1H), 5.38 (dt, J = 10.7, 7.0 Hz,
1H), 4.29 (pentet, J = 7.3 Hz 1H), 4.16 (m, 1H), 4.01 (m, 1H),
3.58 (m, 1H), 3.15 (dd, J = 13.7, 10.2 Hz 1H), 3.00 (dd, J = 13.7,
6.0 Hz, 1H), 2.72 (m, 1H), 2.67 (m, 1H) 2.39 (m, 5H), 1.29 (d, J =
7.2 Hz, 3H), 1.27 (d, J = 7.3 Hz, 3H), 0.95 (d, J = 6.0 Hz, 3H), 0.93
(d, J = 6.0 Hz, 3H). HRMS (ESI-TOF) m/z calcd for C27H38N4O7H
+
531.2819; found 531.2815 [M + H]+. HPLC gradient C, tR =
11.04 min (>95%).
Azumamide D, (Z)-6-[(2R,5R,8R,11R,12S)-8-Benzyl-2,5,12-tri-
methyl-3,6,9,13-tetraoxo-1,4,7,10-tetraazacyclotridecan-11-
yl]hex-4-enamide (8). LiOH (53 mg, 2.21 mmol) in water (5.0 mL)
was added to a stirred solution of the impure cyclic peptide 22
(22.7 mg, approximately 0.044 mmol) in THF (3 mL). After 4 h the
organic solvent was removed in vacuo and the water (0.5 mL) was
added to the aqueous phase, which was then acidiﬁed with 1 M HCl
(2 mL) and extracted with EtOAc (4 × 20 mL). The organic phases
were dried (MgSO4), ﬁltered, and concentrated to give the crude acid
23, which was used without further puriﬁcation. To a solution of the
crude acid 23 (≈23 μmol) in CH2Cl2−DMF (8:1, 2.3 mL) were added
HOBt (10 mg, 66 μmol, 3.0 equiv), DIC (10 μL, 66 μmol, 3 equiv),
and iPr2NEt (15 μL, 88 μmol, 4 equiv). After 5 min, NH3−dioxane
(0.5 M, 0.22 mL, 110 μmol, 5 equiv) was added. After 1 h, NH3−
dioxane (0.5 M, 0.22 mL, 110 μmol, 5 equiv) was added. After the
mixture was stirred for 18 h, additional DMF (0.5 mL) was added,
followed by NH3−MeOH (2.0 M, 0.11 mL, 230 μmol, 10 equiv). After
an additional 5 h, DIC (7 μL, 46 μmol, 2 equiv) was added. The next
day NH3−MeOH (2.0 M, 0.06 mL, 111 μmol, 5 equiv) was added and
the mixture was stirred for 10 days. Finally, DIC (3.4 μL, 23 μmol,
1 equiv) was added, followed by NH3−MeOH (2.0 M, 0.055 mL,
210 μmol, 5 equiv), and after 2 days the mixture was concentrated,
dissolved in MeCN−H2O (2:1), and puriﬁed by preparative HPLC to
aﬀord azumamide D (8) (1.2 mg, 4% overall) as a white solid. [α]D
+32° (c = 0.08, MeOH); previously reported11 [α]D +25° (c = 0.1,
MeOH). 1H NMR (500 MHz, CD3OH) δ 8.03 (d, J = 7.8 Hz, 1H),
8.01 (d, J = 8.8 Hz, 1H) 7.94 (d, J = 6.8 Hz, 1H), 7.58 (s, 1H), 7.32 (d,
J = 7.5 Hz, 1H), 7.25−7.14 (m, 5H), 6.75 (s, 1H), 5.47 (m, 1H),
5.39 (m, 1H), 4.35 (m, 1H), 4.19 (m, 1H) 4.17− 4.11 (m, 2H),
3.09 (m, 2H), 2.69 (m, 1H), 2.62 (m, 1H), 2.41 (m, 2H), 2.28
(m, 1H), 1.47 (d, J = 7.4 Hz, 3H), 1.28 (d, J = 7.4 Hz, 3H), 1.22 (d,
J = 7.3 Hz, 3H). HRMS (ESI-TOF) m/z calcd for C25H35N5O5H
+
486.2716; found 486.2710 [M + H]+. HPLC gradient C, tR =
10.55 min (>95%).
Azumamide E, (Z)-6-[(2R,5R,8R,11R,12S)-8-Benzyl-2-isoprop-
yl-5,12-dimethyl-3,6,9,13-tetraoxo-1,4,7,10-tetraazacyclotride-
can-11-yl]hex-4-enoic Acid (9). LiOH (18.5 mg, 0.77 mmol,
40 equiv) in water (4 mL) was added to a stirred solution of the impure
cyclic peptide 20 (10.5 mg, approximately 0.02 mmol) in THF (4 mL).
After 1 h, LiOH (10 mg, 0.42 mmol, 20 equiv) in water (1 mL) was
added, and after 2 h, LiOH (5.0 mg, 0.21 mmol, 1 equiv) in water
(0.5 mL) was added. The solution was stirred for 16 h and another
portion of LiOH (6.0 mg, 0.25 mmol, 1.3 equiv) in water (0.5 mL)
was added. After an additional 2.5 h of stirring, the organic solvent was
removed in vacuo. The aqueous phase was acidiﬁed with 1 M HCl and
extracted with EtOAc (4 × 25 mL). The combined organic phases
were dried (Na2SO4), ﬁltered, and concentrated. The resulting residue
was dissolved in MeCN−water [(3:2), 2.5 mL] and puriﬁed by
preparative HPLC to aﬀord azumamide E (9) (4.3 mg, 15% overall)
as a white solid. [α]D +66° (c = 0.2, MeOH); previously reported
11
[α]D +53° (c = 0.1, MeOH).
1H NMR (500 MHz, CD3OH)
δ 8.10 (d, J = 7.7 Hz, 1H), 7.95 (d, J = 8.8 Hz, 1H), 7.84 (br s, 1H),
7.63 (d, J = 8.4 Hz, 1H), 7.28−7.16 (m, 5H), 5.48 (m, 1H), 5.37 (m,
1H), 4.28 (pentet, J = 7.5 Hz, 1H), 4.16 (m, 1H), 4.08 (m, 1H), 3.59
(m, 1H), 3.25 (dd, J = 13.6, 10.4 Hz, 1H), 3.11 (dd, J = 13.6, 6.1 Hz,
1H), 2.72 (m, 1H), 2.68 (m, 1H), 2.39 (d, J = 1.7 Hz, 6H), 2.39 (m,
6H), 1.28 (d, J = 7.1 Hz, 3H), 1.27 (d, J = 7.4 Hz, 3H), 0.94 (m, 6H).
HRMS (ESI-TOF) m/z calcd for C27H38N4O6H
+ 515.2869; found
515.2869 [M + H]+. HPLC gradient C, tR = 12.53 min (>95%).
Assay Materials. HDAC1 (purity >45% by SDS−PAGE according
to the supplier), HDAC4 (purity >90% by SDS−PAGE according to
the supplier), and HDAC7 (purity >90% by SDS−PAGE according to
the supplier) were purchased from Millipore (Temecula, CA).
HDAC2 used for dose−response experiments (full length, purity
≥94% by SDS−PAGE according to the supplier), HDAC5 (full length,
purity ≥4% by SDS−PAGE according to the supplier), and HDAC8
used for dose−response experiments (purity ≥90% by SDS−PAGE
according to the supplier) were purchased from BPS Bioscience (San
Diego, CA). HDAC2 used for initial screening experiments (full
length, purity 50% by SDS−PAGE according to the supplier),
HDAC3−“NCoR1” complex [(purity 90% by SDS−PAGE according
to supplier; fusion protein of GST-tagged HDAC3 with the
deacetylase activation domain (DAD) of NCoR1 (nuclear receptor
corepressor)], HDAC6 (purity >90% by SDS−PAGE according to the
supplier), HDAC8 for initial screening experiments (purity >50% by
SDS−PAGE according to the supplier), HDAC10 (purity >50% by
SDS−PAGE according to the supplier), and HDAC11 (purity >50%
by SDS−PAGE according to the supplier) were purchased from Enzo
Life Sciences (Postfach, Switzerland). HDAC9 (full length, purity 12%
by SDS−PAGE according to the supplier) was purchased from
Abnova (Taipei, Taiwan). The HDAC assay buﬀer consisted of
50 mM Tris-HCl, pH 8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2,
and bovine serum albumin (0.5 mg/mL). Trypsin [10 000 units/mg;,
from bovine pancreas, treated with L-(tosylamido-2-phenyl)ethyl chloro-
methyl ketone (TPCK)] was from Sigma Aldrich (Steinheim, Germany).
All peptides were puriﬁed to homogeneity (>95% purity by
HPLC230nm via reversed-phase preparative HPLC), and the white
ﬂuﬀy materials obtained by lyophilization were kept at −20 °C. For
assaying, peptides were reconstituted in DMSO to give 5−10 mM
stock solutions, the accurate concentrations of which were determined
by coinjection on HPLC with a standard of known concentration.
In Vitro Histone Deacetylase Inhibition Assays. For inhibition
of recombinant human HDACs, dose−response experiments with
internal controls were performed in black low-binding Nunc 96-well
microtiter plates. Dilution series (3-fold dilution, 10 concentrations)
were prepared in HDAC assay buﬀer from 5−10 mM DMSO stock
solutions. The appropriate dilution of inhibitor (10 μL of 5× the
desired ﬁnal concentration) was added to each well followed by
HDAC assay buﬀer (25 μL) containing substrate [Ac-Leu-Gly-
Lys(Ac)-AMC, 40 μM for HDAC1−3 and 80 μM for HDAC6 and
11; Ac-Leu-Gly-Lys(Tfa)-AMC, 40 μM for HDAC4, 240 μM for
HDAC5, 80 μM for HDAC7, 400 μM for HDAC8, and 160 μM for
HDAC9; Ac-Arg-His-Lys(Ac)-Lys(Ac)-AMC, 100 μM for HDAC10].
Finally, a solution of the appropriate HDAC (15 μL) was added
and the plate was incubated at 37 °C for 30 min [HDAC1, 150 ng/well;
HDAC2, 100 ng/well; HDAC3, 10 ng/well; HDAC4, 2 ng/well;
HDAC5, 40 ng/well; HDAC6, 60 ng/well; HDAC7, 2 ng/well; HDAC8,
5 ng/well; HDAC9, 40 ng/well; HDAC10, 500 ng/well; HDAC11,
500 ng/well]. Then trypsin (50 μL, 0.4 mg/mL) was added and the
assay development was allowed to proceed for 15−30 min at room
temperature, before the plate was read on a Perkin-Elmer Enspire
plate reader with excitation at 360 nm and detecting emission at 460 nm.
Each assay was performed in duplicate. The data were analyzed by
nonlinear regression with GraphPad Prism to aﬀord IC50 values from the
dose−response experiments, and Ki values were determined from the
Cheng−Prusoﬀ equation [Ki = IC50/(1 + [S]/Km)] with the assumption
of a standard fast-on−fast-oﬀ mechanism of inhibition.
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